Dayan JH, Ly CL, Kataru RP, Mehrara BJ. Lymphedema: pathogenesis and novel therapies. Annu Rev Med. 2018;69:263–76. https://doi.org/10.1146/annurev-med-060116-022900.
Article CAS PubMed Google Scholar
Greene AK, Goss JA. Diagnosis and staging of lymphedema. Semin Plast Surg. 2018;32(1):12–6. https://doi.org/10.1055/s-0038-1635117.
Article PubMed PubMed Central Google Scholar
Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008;1131:147–54. https://doi.org/10.1196/annals.1413.014.
DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15. https://doi.org/10.1016/s1470-2045(13)70076-7.
Warren AG, Brorson H, Borud LJ, Slavin SA. Lymphedema: a comprehensive review. Ann Plast Surg. 2007;59(4):464–72. https://doi.org/10.1097/01.sap.0000257149.42922.7e.
Article CAS PubMed Google Scholar
Rockson SG. Lymphedema after breast cancer treatment. N Engl J Med. 2018;379(20):1937–44. https://doi.org/10.1056/NEJMcp1803290.
Salinas-Huertas S, Luzardo-González A, Vázquez-Gallego S, et al. Risk factors for lymphedema after breast surgery: a prospective cohort study in the era of sentinel lymph node biopsy. Breast Dis. 2021. https://doi.org/10.3233/bd-210043.
Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010;116(22):5138–49. https://doi.org/10.1002/cncr.25458.
Beaulac SM, McNair LA, Scott TE, LaMorte WW, Kavanah MT. Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg. 2002;137(11):1253–7. https://doi.org/10.1001/archsurg.137.11.1253.
Heiney SP, McWayne J, Cunningham JE, et al. Quality of life and lymphedema following breast cancer. Lymphology. 2007;40(4):177–84.
Pusic AL, Cemal Y, Albornoz C, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Surviv. 2013;7(1):83–92. https://doi.org/10.1007/s11764-012-0247-5.
Shih YC, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27(12):2007–14. https://doi.org/10.1200/JCO.2008.18.3517.
Taghian NR, Miller CL, Jammallo LS, O’Toole J, Skolny MN. Lymphedema following breast cancer treatment and impact on quality of life: a review. Crit Rev Oncol Hematol. 2014;92(3):227–34. https://doi.org/10.1016/j.critrevonc.2014.06.004.
Yuan Y, Arcucci V, Levy SM, Achen MG. Modulation of immunity by lymphatic dysfunction in lymphedema. Front Immunol. 2019;10:76. https://doi.org/10.3389/fimmu.2019.00076.
Article CAS PubMed PubMed Central Google Scholar
Armer J, Porock D. Self-management of fatigue among women with lymphedema. Lymphology. 2002;35(Suppl):208–13.
De Vrieze T, Nevelsteen I, Thomis S, et al. What are the economic burden and costs associated with the treatment of breast cancer-related lymphoedema? A systematic review. Support Care Cancer. 2020;28(2):439–49. https://doi.org/10.1007/s00520-019-05101-8.
Barufi S, Pereira de Godoy HJ, Pereira de Godoy JM, Guerreiro Godoy MF. Exercising and compression mechanism in the treatment of lymphedema. Cureus. 2021;13(7):e16121. https://doi.org/10.7759/cureus.16121.
Article PubMed PubMed Central Google Scholar
Uzkeser H, Karatay S, Erdemci B, Koc M, Senel K. Efficacy of manual lymphatic drainage and intermittent pneumatic compression pump use in the treatment of lymphedema after mastectomy: a randomized controlled trial. Breast Cancer (Tokyo, Japan). 2015;22(3):300–7. https://doi.org/10.1007/s12282-013-0481-3.
Keith L, Rowsemitt C, Richards LG. Lifestyle modification group for lymphedema and obesity results in significant health outcomes. Am J Lifestyle Med. 2020;14(4):420–8. https://doi.org/10.1177/1559827617742108.
Schmitz KH, Troxel AB, Dean LT, et al. Effect of home-based exercise and weight loss programs on breast cancer-related lymphedema outcomes among overweight breast cancer survivors: the WISER survivor randomized clinical trial. JAMA Oncol. 2019;5(11):1605–13. https://doi.org/10.1001/jamaoncol.2019.2109.
Article PubMed PubMed Central Google Scholar
Kayıran O, De La Cruz C, Tane K, Soran A. Lymphedema: from diagnosis to treatment. Turk J Surg. 2017;33(2):51–7. https://doi.org/10.5152/turkjsurg.2017.3870.
Article PubMed PubMed Central Google Scholar
Carl HM, Walia G, Bello R, et al. Systematic review of the surgical treatment of extremity lymphedema. J Reconstr Microsurg. 2017;33(6):412–25. https://doi.org/10.1055/s-0037-1599100.
Forte AJ, Boczar D, Huayllani MT, Lu X, McLaughlin SA. Pharmacotherapy agents in lymphedema treatment: a systematic review. Cureus. 2019;11(12):e6300. https://doi.org/10.7759/cureus.6300.
Article PubMed PubMed Central Google Scholar
Walker J, Tanna S, Roake J, Lyons O. A systematic review of pharmacologic and cell-based therapies for treatment of lymphedema (2010–2021). J Vasc Surg Venous Lymphatic Disord. 2021. https://doi.org/10.1016/j.jvsv.2021.09.004.
Badger C, Seers K, Preston N, Mortimer P. Antibiotics / anti-inflammatories for reducing acute inflammatory episodes in lymphoedema of the limbs. Cochrane Database Syst Rev. 2004;2:Cd003143. https://doi.org/10.1002/14651858.CD003143.pub2.
Forte AJ, Boczar D, Huayllani MT, McLaughlin SA, Bagaria S. Topical approach to delivering targeted therapies in lymphedema treatment: a systematic review. Cureus. 2019;11(12):e6269. https://doi.org/10.7759/cureus.6269.
Article PubMed PubMed Central Google Scholar
Forte AJ, Boczar D, Huayllani MT, McLaughlin SA, Bagaria S. Use of gene transfer vectors in lymphedema treatment: a systematic review. Cureus. 2019;11(10):e5887. https://doi.org/10.7759/cureus.5887.
Article PubMed PubMed Central Google Scholar
Forte AJ, Boczar D, Huayllani MT, Cinotto GJ, McLaughlin S. Targeted therapies in surgical treatment of lymphedema: a systematic review. Cureus. 2019;11(8):e5397. https://doi.org/10.7759/cureus.5397.
Article PubMed PubMed Central Google Scholar
Secker GA, Harvey NL. Regulation of VEGFR signalling in lymphatic vascular development and disease: an update. Int J Mol Sci. 2021;22(14). https://doi.org/10.3390/ijms22147760.
Lahdenranta J, Hagendoorn J, Padera TP, et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Can Res. 2009;69(7):2801–8. https://doi.org/10.1158/0008-5472.Can-08-4051.
Mäkinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7(2):199–205. https://doi.org/10.1038/84651.
Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 2005;97(1):14–21. https://doi.org/10.1093/jnci/dji003.
Article CAS PubMed Google Scholar
Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001;20(6):1223–31. https://doi.org/10.1093/emboj/20.6.1223.
Article CAS PubMed PubMed Central Google Scholar
Oh SJ, Jeltsch MM, Birkenhäger R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol. 1997;188(1):96–109. https://doi.org/10.1006/dbio.1997.8639.
Article CAS PubMed Google Scholar
Mäkinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001;20(17):4762–73. https://doi.org/10.1093/emboj/20.17.4762.
Article PubMed PubMed Central Google Scholar
Zarkada G, Heinolainen K, Makinen T, Kubota Y, Alitalo K. VEGFR3 does not sustain retinal angiogenesis without VEGFR2. Proc Natl Acad Sci USA. 2015;112(3):761–6. https://doi.org/10.1073/pnas.1423278112.
Article CAS PubMed PubMed Central Google Scholar
Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA. 2001;98(22):12677–82. https://doi.org/10.1073/pnas.221449198.
Article CAS PubMed PubMed Central Google Scholar
Szuba A, Skobe M, Karkkainen MJ, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002;16(14):1985–7. https://doi.org/10.1096/fj.02-0401fje.
Article CAS PubMed Google Scholar
Cheung L, Han J, Beilhack A, et al. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. BioDrugs. 2006;20(6):363–70. https://doi.org/10.2165/00063030-200620060-00007.
Jin DP, An A, Liu J, Nakamura K, Rockson SG. Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization. Lymphat Res Biol. 2009;7(1):47–57. https://doi.org/10.1089/lrb.2009.0002.
Comments (0)